Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new public-private consortium (known as COMPACT) funded by the Innovative Medicines Initiative (IMI) of the EU recently launched a major new 30 million Euro project focussing on improving the delivery of biopharmaceutical drugs. The University of Oxford plays a leading
role in the consortium which also comprises experts from 14 academic institutions, two biotechnology companies and seven pharmaceutical companies. Professor Matthew Wood will lead all IMI work to develop improved methods for drug delivery to the brain. A major challenge in treating many currently incurable neurological diseases is to achieve effective drug delivery to the brain across the blood brain barrier (a natural barrier that protects the brain). This new IMI project aims to tackle this challenge within the next 5 years.

Similar stories

The brain’s one-sided teaching signals

A new study by the Lak group reveals a novel facet of dopamine signalling during visual decision making.

Fellowship awarded to Huriye Atilgan to enhance our understanding of value-based decision-making

Congratulations are in order for Postdoctoral Research Scientist Dr Huriye Atilgan who has been awarded a prestigious Sir Henry Wellcome Postdoctoral Fellowship funded by the Wellcome Trust.

The future of stroke treatment

A team of international collaborators including DPAG's Dr Mootaz Salman has been researching a promising new therapeutic for the treatment of strokes and other brain injuries.

Frances Ashcroft and Denis Noble honoured by the IUPS Academic of Physiology

Professors Dame Frances Ashcroft and Denis Noble have been elected Fellows of the the International Union of Physiological Sciences (IUPS) Academy of Physiology in the inaugural year of its Fellowships.

New review reveals proof of concept for an anti-obesity immunotherapy

The Domingos lab has published a new opinion piece in Science investigating the implications of a Memorial Sloan Kettering Cancer Center study that lays the foundations for a potential new anti-obesity treatment in the form of targeting adipose tissue-resident macrophages.